N-[(5-methylpyrazin-2-yl)methyl]-2-morpholin-4-yl-5-oxo-[1,3]benzothiazolo[3,2-a][1,8]naphthyridine-6-carboxamide | 1138546-56-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: N-[(5-methylpyrazin-2-yl)methyl]-2-morpholin-4-yl-5-oxo-[1,3]benzothiazolo[3,2-a][1,8]naphthyridine-6-carboxamide
• CAS: 1138546-56-1
• 化学式: C₂₅H₂₂N₆O₃S
• 分子量: 486.554
• InChiKey: YKZHYSGQYOORGC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  35
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  126
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  2,6-二氯吡啶-3-羰酰氯 在 aluminum (III) chloride 、 三乙胺 、 magnesium chloride 作用下， 以 N-甲基吡咯烷酮 、 二氯甲烷 、 乙腈 为溶剂， 反应 2.0h， 生成 N-[(5-methylpyrazin-2-yl)methyl]-2-morpholin-4-yl-5-oxo-[1,3]benzothiazolo[3,2-a][1,8]naphthyridine-6-carboxamide
  参考文献：
  名称：

  Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics

  摘要：

  Accelerated proliferation of solid tumor and hematologic cancer cells is linked to accelerated transcription of rDNA by the RNA polymerase I (Pol I) enzyme to produce elevated levels of rRNA (rRNA). Indeed, upregulation of Pol I, frequently caused by mutational alterations among tumor suppressors and oncogenes, is required for maintenance of the cancer phenotype and forms the basis for seeking selective inhibitors of Pot I as anticancer therapeutics. 2-(4-Methyl-[1,4]diazepan-1-yl)-5-oxo-5H-7-thia-1,11b-diaza-benzo[c]fluorene-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide (CX-5461, 7c) has been identified as the first potent, selective, and orally bioavailable inhibitor of RNA Pot I transcription with in vivo activity in tumor growth efficacy models. The preclinical data support the development of CX-5461 as an anticancer drug with potential for activity in several types of cancer.

  DOI：

  10.1021/ml300110s

文献信息

• QUINOLONE ANALOGS AND METHODS RELATED THERETO
  申请人：NAGASAWA Johnny Yasuo

  公开号：US20090093455A1

  公开（公告）日：2009-04-09

  The present invention provides novel quinolone compounds and pharmaceutical composition thereof which may inhibit cell proliferation and/or induce cell apoptosis. The present invention also provides methods of preparing such compounds and compositions, and methods of making and using the same.

  本发明提供了新型喹诺酮化合物及其药物组合物，可以抑制细胞增殖和/或诱导细胞凋亡。本发明还提供了制备这种化合物和组合物的方法，以及制备和使用它们的方法。
• [EN] QUINOLONE ANALOGS AND METHODS RELATED THERETO<br/>[FR] ANALOGUES DE QUINOLONE ET PROCÉDÉS ASSOCIÉS
  申请人：CYLENE PHARMACEUTICALS INC

  公开号：WO2009046383A1

  公开（公告）日：2009-04-09

  The present invention provides novel quinolone compounds and pharmaceutical composition thereof which may inhibit cell proliferation and/or induce cell apoptosis. The present invention also provides methods of preparing such compounds and compositions, and methods of making and using the same.

  本发明提供了新型的喹诺酮化合物及其制药组合物，可抑制细胞增殖和/或诱导细胞凋亡。本发明还提供了制备这种化合物和组合物的方法，以及使用它们的方法。
• US7928100B2
  申请人：——

  公开号：US7928100B2

  公开（公告）日：2011-04-19
• US8853234B2
  申请人：——

  公开号：US8853234B2

  公开（公告）日：2014-10-07
• Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics
  作者：Mustapha Haddach、Michael K. Schwaebe、Jerome Michaux、Johnny Nagasawa、Sean E. O'Brien、Jeffrey P. Whitten、Fabrice Pierre、Pauline Kerdoncuff、Levan Darjania、Ryan Stansfield、Denis Drygin、Kenna Anderes、Chris Proffitt、Josh Bliesath、Adam Siddiqui-Jain、May Omori、Nanni Huser、William G. Rice、David M. Ryckman

  DOI：10.1021/ml300110s

  日期：2012.7.12

  Accelerated proliferation of solid tumor and hematologic cancer cells is linked to accelerated transcription of rDNA by the RNA polymerase I (Pol I) enzyme to produce elevated levels of rRNA (rRNA). Indeed, upregulation of Pol I, frequently caused by mutational alterations among tumor suppressors and oncogenes, is required for maintenance of the cancer phenotype and forms the basis for seeking selective inhibitors of Pot I as anticancer therapeutics. 2-(4-Methyl-[1,4]diazepan-1-yl)-5-oxo-5H-7-thia-1,11b-diaza-benzo[c]fluorene-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide (CX-5461, 7c) has been identified as the first potent, selective, and orally bioavailable inhibitor of RNA Pot I transcription with in vivo activity in tumor growth efficacy models. The preclinical data support the development of CX-5461 as an anticancer drug with potential for activity in several types of cancer.